Key People/Management at Partner Therapeutics

Bill McClements

Bill McClements

Chief Financial and Operations Officer
Dave Carlson

Dave Carlson

Vice President Manufacturing
Sarah Kurz

Sarah Kurz

Executive Vice President
Robert Mulroy

Robert Mulroy

Chief Executive Officer
Debasish Roychowdhury

Debasish Roychowdhury

Chief Medical Officer
John McManus

John McManus

Chief Business Officer
Show more

Partner Therapeutics Office Locations

Partner Therapeutics has offices in Lexington, Boston and Lynnwood
Lexington, MA, US (HQ)
19 Muzzey St
Boston, MA, US
1 Marina Park Drive #900
Lynnwood, WA, US
2625 162nd St SW
Show all (3)

Partner Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2017

Partner Therapeutics total Funding

$60 m

Partner Therapeutics latest funding size

$60 m

Time since last funding

4 years ago

Partner Therapeutics investors

Partner Therapeutics's latest funding round in February 2018 was reported to be $60 m. In total, Partner Therapeutics has raised $60 m
Show all financial metrics

Partner Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Partner Therapeutics Online and Social Media Presence

Embed Graph

Partner Therapeutics News and Updates

Partner Therapeutics Initiates Patient Enrollment in Clinical Trial Evaluating Leukine® (rhuGM-CSF, sargramostim) in High-risk Non-hospitalized COVID-19 Patients (SCOPE)

LEXINGTON, Mass., April 29, 2021 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today that the first patient has been enrolled in the SCOPE clinical trial, a randomized, placebo-controlled, double-blind phase 2 study of inhaled Leukine...

Partner Therapeutics Announces Publication of Clinical Trial Results Showing Significant Benefit with Use of Leukine® (sargramostim) in Patients with Alzheimer's Disease

LEXINGTON, Mass., March 24, 2021 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the publication of results from an investigator-initiated clinical trial (NCT01409915) evaluating the use of Leukine® (sargramostim, yeast-derived rhuGM-CSF) in...

Partner Therapeutics Announces Partnership with SIRS Therapeutics and F4 Pharma to Explore Potential Uses for FX06 in Biodefense Applications

LEXINGTON, Mass., March 3, 2021 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces a licensing and collaboration agreement with Munich-based SIRS Theraputics and Vienna-based F4 Pharma to support the development of FX-06, a synthetic peptide that has...

Partner Therapeutics Announces Publication of Two Studies Demonstrating Leukine® Improves Survival in Acute Radiation Syndrome (ARS)

LEXINGTON, Mass., Feb. 18, 2021 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces publication of two pivotal studies that provided the basis for approval of Leukine (sargramostim, yeast-derived rhu GM-CSF) to improve survival in patients expoed to...

Partner Therapeutics Announces Start of Phase 3 Portion of Clinical Study of Leukine® in Combination with Ipilumimab and Nivolumab in Front Line Treatment of Melanoma

LEXINGTON, Mass., Sept. 11, 2020 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the resumption of enrollment in the National Cancer Institute (NCI) sponsored Study EA61411 being conducted by ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and led...

Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine® in Patients with COVID-19 Associated Respiratory Illness

LEXINGTON, Mass., March 24, 2020 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) announced that Leukine® (sargramostim, rhu-GM-CSF) is being assessed in the SARPAC trial (sargramostim in patients with acute hypoxic respiratory failure due to COVID-19 – EudraCT #2020-001254-22) at...
Show more

Partner Therapeutics Blogs

“A Drug Before Its Time?” LEUKINE® systematic review highlights innate and adaptive immune activity that may improve cancer outcomes and reduce toxicity

Authors also highlight promising data in neurodegenerative diseases, fungal infection, and respiratory diseases including aPAP and COVID-19 Lexington, MA – August 17, 2021 /PRNewswire/ — Partner Therapeutics, Inc. (PTx) announced today that Frontiers in Immunology published a systematic review of LE…

Partner Therapeutics Announces Publication of Clinical Trial Results of Leukine® (sargramostim) in Patients with Parkinson’s Disease

Immune transformation after intermittent dosing with Leukine shows promise for Parkinson’s disease LEXINGTON, MA – May 19, 2021 — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the publication of results from an investigator-initiated clinical trial (NCT03790670) evaluatin…

Partner Therapeutics Announces Publication of Clinical Trial Results Showing Significant Benefit with Use of Leukine® (sargramostim) in Patients with Alzheimer’s Disease

Patients with mild-to-moderate Alzheimer’s disease (AD) receiving Leukine experienced significant reversal of cognitive loss and biomarkers of disease progression while taking Leukine Study shows Leukine safe and tolerable and concludes that the innate immune system is a viable target for therapeuti…

Partner Therapeutics Frequently Asked Questions

  • When was Partner Therapeutics founded?

    Partner Therapeutics was founded in 2017.

  • Who are Partner Therapeutics key executives?

    Partner Therapeutics's key executives are Bill McClements, Dave Carlson and Sarah Kurz.

  • How many employees does Partner Therapeutics have?

    Partner Therapeutics has 178 employees.

  • Who are Partner Therapeutics competitors?

    Competitors of Partner Therapeutics include Halozyme Therapeutics, CARsgen Therapeutics and OncoTherapy Science.

  • Where is Partner Therapeutics headquarters?

    Partner Therapeutics headquarters is located at 19 Muzzey St, Lexington.

  • Where are Partner Therapeutics offices?

    Partner Therapeutics has offices in Lexington, Boston and Lynnwood.

  • How many offices does Partner Therapeutics have?

    Partner Therapeutics has 3 offices.